Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 19/20 | 0.50 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.50 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.50 |
| ▸ | CDK9 | P50750 | 18/20 | 0.48 |
| ▸ | CDK7 | P50613 | 2/20 | 0.48 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.48 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.48 |
| ▸ | CCNH | P51946 | 1/20 | 0.48 |
| ▸ | CDK4 | P11802 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10324747 | 0.87 | CDK2 (0.54) | CDK2CDK5CDK5R1CDK9CDK7 | |
| SCHEMBL7886130 | 0.83 | USP1 (0.51) | CDK2CDK5CDK5R1CDK9CDK7 | |
| SCHEMBL10323982 | 0.83 | CDK2 (0.45) | CDK2CDK5CDK5R1CDK9CDK7 | |
| SCHEMBL7895863 | 0.82 | CDK2 (0.65) | CDK2CDK5CDK5R1CDK9CDK7 | |
| SCHEMBL29842280 | 0.82 | CDK2 (0.51) | CDK2CDK5CDK5R1CDK9CDK7 | |
| SCHEMBL18073030 | 0.82 | CDK2 (0.51) | CDK2CDK5CDK5R1CDK9CDK7 | |
| SCHEMBL7883742 | 0.81 | CDK2 (0.51) | CDK2CDK5CDK5R1CDK9CDK7 | |
| SCHEMBL19912776 | 0.79 | CDK2 (0.54) | CDK2CDK9CDK7CDK4 | |
| SCHEMBL6895325 | 0.77 | SRC (0.47) | CDK2 | |
| SCHEMBL18050975 | 0.77 | CDK2 (0.45) | CDK2CDK5CDK5R1CDK9CDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8691982-B2 | Pyrazolo[1,5-a]-1,3,5-triazine derivatives, preparation thereof, and therapeutic use thereof | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2014-04-08 | — | — | US | disclosed |
| US-8691982-B2 | Pyrazolo[1,5-a]-1,3,5-triazine derivatives, preparation thereof, and therapeutic use thereof | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2014-04-08 | — | — | US | disclosed |
| EP-2406263-B1 | PYRAZOLO[1,5-A]-1,3,5-TRIAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | CENTRE NAT RECH SCIENT (FR) | 2013-09-25 | — | — | EP | disclosed |
| EP-2406263-B1 | PYRAZOLO[1,5-A]-1,3,5-TRIAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | CENTRE NAT RECH SCIENT (FR) | 2013-09-25 | — | — | EP | disclosed |
| US-20120184557-A1 | PYRAZOLO[1,5-A]-1,3,5-TRIAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-07-19 | — | — | US | disclosed |
| US-20120184557-A1 | PYRAZOLO[1,5-A]-1,3,5-TRIAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-07-19 | — | — | US | disclosed |
| US-20120184557-A1 | PYRAZOLO[1,5-A]-1,3,5-TRIAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-07-19 | — | — | US | disclosed |
| US-20120149708-A1 | MODULATORS OF VIRAL TRANSCRIPTION, AND METHODS AND COMPOSITIONS THEREWITH | GEORGE MASON UNIVERSITY | 2012-06-14 | — | — | US | disclosed |
| US-20120149708-A1 | MODULATORS OF VIRAL TRANSCRIPTION, AND METHODS AND COMPOSITIONS THEREWITH | GEORGE MASON UNIVERSITY | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149708-A1 | MODULATORS OF VIRAL TRANSCRIPTION, AND METHODS AND COMPOSITIONS THEREWITH | CDK2, CCNA1, CDK1 | CDK2 1/4885CDK5 23/4885CDK5R1 36/4885 |
| US-20120184557-A1 | PYRAZOLO[1,5-A]-1,3,5-TRIAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | AOC3, CBR3, RTN3 | CDK2 1344/4885CDK5 1491/4885CDK5R1 916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.